Cargando…

Burden of disease among patients with prevalent Crohn’s disease: results from a large German sickness fund

PURPOSE: The aim of this study was to investigate the burden of disease among a real-world cohort of patients with prevalent Crohn’s disease (CD) in Germany. METHODS: We conducted a retrospective cohort analysis using administrative claims data from the German AOK PLUS health insurance fund. Continu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuleku, Evi, Antolin-Fontes, Beatriz, Borsi, Andras, Nissinen, Riikka, Bravatà, Ivana, Barthelmes, Jennifer Norma, Lee, Jennifer, Passey, Alun, Wirth, Daniel, Maywald, Ulf, Bokemeyer, Bernd, Wilke, Thomas, Ghiani, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027629/ https://www.ncbi.nlm.nih.gov/pubmed/36939923 http://dx.doi.org/10.1007/s00384-023-04368-y

Ejemplares similares

Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn’s Disease patients: A retrospective analysis using German claims data
por: Zhuleku, Evi, et al.
Publicado: (2022)

Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS)
por: Ghiani, Marco, et al.
Publicado: (2023)

P40 REAL-WORLD TREATMENT PATTERNS OF PATIENTS INITIATING THIRD-LINE THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN EUROPE
por: Lehne, M., et al.
Publicado: (2023)

P958: REAL-WORLD TREATMENT PATTERNS IN PATIENTS INITIATING THIRD-LINE THERAPY FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN GERMANY, ITALY, THE UK, FRANCE, AND SPAIN
por: Ramasamy, Karthik, et al.
Publicado: (2023)

P21 Social Distancing and Trends in Influenza Hospitalization during the COVID-19 Outbreak: A Difference-in-Difference Analysis of German Claims Data
por: Pacis, S, et al.
Publicado: (2022)

POSA32 Early COVID-19 Pandemic in Germany: Patient Characteristics and Clinical Outcomes
por: Pacis, S, et al.
Publicado: (2022)

EPH35 Post-COVID Conditions in Hospitalized COVID-19 Patients in Germany
por: Pacis, S, et al.
Publicado: (2022)

Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting
por: Bokemeyer, B., et al.
Publicado: (2020)

Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data
por: Constantin, Joelle, et al.
Publicado: (2019)

Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events
por: Hardtstock, Fränce, et al.
Publicado: (2021)

POSB189 Mental Health in COVID Times: A Quasi-Experimental Analysis of the Impact of Lockdown Measures on Mental Healthcare Use in Germany
por: Ghiani, M, et al.
Publicado: (2022)

Health Literacy Research Funded by the NIH for Disease Prevention
por: Villani, Jennifer, et al.
Publicado: (2020)

Disease and Sickness
Publicado: (1890)

Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
por: af Björkesten, Clas-Göran, et al.
Publicado: (2020)

POSA52 A Year-on-Year Comparison Overall German Healthcare Resource Utilization in COVID Versus Non-COVID Times: A German Claims Data Analysis
por: Mevius, A, et al.
Publicado: (2022)

EPH144 The Impact of COVID-19 Pandemic on the Detection and Management of Cancer: A German Claims Data Analysis
por: Mevius, A, et al.
Publicado: (2022)

P64 Evaluating the Impact of the COVID-19 Pandemic on Mortality after Myocardial Infarctions Hospitalization in Germany
por: Krieger, J, et al.
Publicado: (2022)

Zinc in Human Health and Infectious Diseases
por: Maywald, Martina, et al.
Publicado: (2022)

The Effectiveness of the Cardiovascular Disease Prevention Programme ‘KardioPro’ Initiated by a German Sickness Fund: A Time-to-Event Analysis of Routine Data
por: Witt, Sabine, et al.
Publicado: (2014)

Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real‐world data analysis
por: Banon, Tamar, et al.
Publicado: (2022)

Funding innovation in neglected diseases
por: Yamey, Gavin, et al.
Publicado: (2018)

Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis
por: Buhl, Roland, et al.
Publicado: (2022)

NIH Disease Funding Levels and Burden of Disease
por: Gillum, Leslie A., et al.
Publicado: (2011)

Breast Cancer Attributable Costs in Germany: A Top-Down Approach Based on Sickness Funds Data
por: Gruber, Emil Victor, et al.
Publicado: (2012)

Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study
por: Tillett, William, et al.
Publicado: (2023)

Liver disease epidemiology and burden in patients with alterations in plasma protein metabolism: German retrospective insurance claims analysis
por: Picker, Nils, et al.
Publicado: (2023)

Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds
por: Wilke, Thomas, et al.
Publicado: (2022)

The cost burden of Crohn’s disease and ulcerative colitis depending on biologic treatment status – a Danish register-based study
por: Alulis, Sarah, et al.
Publicado: (2021)

Extraintestinal Manifestations and Other Comorbidities in Ulcerative Colitis and Crohn Disease: A Danish Nationwide Registry Study 2003–2016
por: Vadstrup, Kasper, et al.
Publicado: (2020)

Including refugees in disease elimination: challenges observed from a sleeping sickness programme in Uganda
por: Palmer, Jennifer J., et al.
Publicado: (2017)

Is adiposopathy (sick fat) an endocrine disease?
por: Bays, H E, et al.
Publicado: (2008)

Art and Disease: VI. Healing of the Sick
Publicado: (1894)

Right sizing funding for Alzheimer's disease
por: Golde, Todd E, et al.
Publicado: (2011)

Analyzing Media Coverage of the Global Fund Diseases Compared with Lower Funded Diseases (Childhood Pneumonia, Diarrhea and Measles)
por: Hudacek, David L., et al.
Publicado: (2011)

Motion sickness susceptibility and visually induced motion sickness as diagnostic signs in Parkinson’s disease
por: Petel, Arthur, et al.
Publicado: (2022)

To fund or not to fund?
por: Shailes, Sarah
Publicado: (2017)

Summer "Sickness and Diarrhœa.": The Treatment of the Disease in Children
por: Heaney, J. H.
Publicado: (1912)

Sick Leave Patterns in Common Rheumatological Diseases
por: Jali, Ibtisam M
Publicado: (2023)

Editorial: The Different Faces of Sickness
por: Rademacher, Lena, et al.
Publicado: (2021)

Who funds Alzheimer's disease drug development?
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_63kk7sv8e3pq5ao5aphok417q7